What Makes a Biomaterial Truly Biocompatible?
A biomaterial must be biologically acceptable or biocompatible to the host cells and tissues to be used in tissue regeneration, replacement therapy, or diagnosis. The capacity of a material to carry out its intended role in the human body and cause the right reaction is known as biocompatibility, and it is a complicated subject. It is dictated by the degree to which the biomaterial's surface interacts with live tissues to facilitate processes, including cell adhesion, proliferation, and differentiation.
However, surface interactions are not the only factor determining whether a biomaterial is biocompatible. A biomaterial may become non-biocompatible if it contains leachable harmful chemicals. This is frequently a problem with synthetic polymers, as impurities like unreacted monomers or additives can lead to immunological responses, implant rejection, and cell injury. Biocompatibility requires the absence of harmful contaminants; however, it is inadequate because many materials may be cytotoxic (toxic to cells) by nature because of their molecular makeup. Therefore, extensive testing is necessary to ascertain the biocompatibility of a substance.
What Is the Use of Biomaterials in Gastrointestinal Disorders?
-
Biomaterials in Regenerative Gastroenterology: Biomaterials are essential to tissue engineering (TE) and regenerative medicine (RM) because they support the proliferation of new cells and facilitate the healing of injured tissues. TE, which varies from typical implants in that it promotes new tissue growth from cells, focuses on developing functional replacements to restore tissue functions impaired by trauma, illness, or aging. As a fundamental element of RM, tissue engineering (TE) attempts to achieve genuine regeneration instead of mere repair by growing new tissues, cells, or organs instead of old ones. The subject of regenerative gastroenterology was born out of the need for novel approaches beyond current treatment regimens to regenerate the complicated gastrointestinal (GI) tract, frequently affected by disorders such as cancer or inflammatory diseases.
-
Biomaterials in Drug Delivery for GI Disorders - Delivering medications to the right locations in the digestive tract is a major difficulty in managing the symptoms of gastrointestinal (GI) illnesses. As carriers of drugs, biomaterials provide potential options that improve the stability, absorption, and specific release of medications. Medicines can be encased in hydrogels, nanoparticles, and microparticles made of biocompatible materials. This protects the medications from the stomach environment and guarantees their release at the correct points in the intestines.
-
Biomaterials in Endoscopic Procedures - The use of biomaterials in endoscopic treatments to treat gastrointestinal problems is growing. Esogastric varices are dilated veins in the GI tract that are induced by portal hypertension, which is frequently brought on by end-stage liver disease such as cirrhosis (liver scarring and fibrosis). These varieties include esophageal (EVs) and gastric (GVs). Though GVs are less prevalent than EVs, their rupture causes significant hemorrhage and a high death rate. Hemostatic agents (such as hemospray, which is a mineral powder that encourages hemostasis and can be used endoscopically), balloon tamponade (the balloon is inserted and inflated to stop hemorrhage), variceal band ligation (a process that treats varices or swollen veins in the esophagus, with elastic bands), self-expanding esophageal stents (a tube that is used for keeping a hollow structure open), and cyanoacrylate glue are among the endoscopic techniques that are recommended for the treatment of these varices. These techniques deal with different GI tract variations.
-
Biomaterials in Endoscopic Bariatric Therapies - The goal of bariatrics is to manage obesity, which is acknowledged as a worldwide problem. For patients who do not qualify for surgery or who refuse it, endoscopic bariatric treatments, or EBTs, have been created as an alternative to lifestyle changes as a means of achieving weight loss. Since EBTs stay near the GI system, there is a higher chance of problems such as tissue reactions, reflux, nausea, and ulcers. Aspiration tubes, electrical stimulators, bypass liners, intragastric balloons, and restriction devices are among the majority that are still at the experimental stage. While certain adverse effects have been reported, no research has discovered a connection between these and the materials' biocompatibility. However, because biomaterials typically stay in contact with GI tissues for an extended time, their impact is extremely significant to understand.
-
Biomaterials in Acid Reflux Disease - Gastroesophageal reflux disease (GERD) is a chronic condition caused by defects in the lower esophageal sphincter (LES). It is commonly treated with lifestyle changes, medications, surgery, and endoscopic devices. Due to the low acceptance of surgery, endoscopic treatments have advanced significantly over the past two decades. Current endoscopic anti-reflux procedures fall into three categories: fundoplication technique that involves tightening of the sphincter between the esophagus and stomach, electrothermal LES (lower esophageal sphincter) treatment, and injection or implantation of bulking materials. Most older devices were removed from the market due to poor performance and side effects. The devices currently in practice create esophagogastric applications using polypropylene fasteners and titanium staples, respectively, known for their biocompatibility. Reported complications have not been linked to the materials themselves.
Conclusion
Due to its ability to facilitate advancements in tissue regeneration, targeted drug delivery, and minimally invasive procedures, biomaterials have completely changed the way that gastrointestinal problems are treated. While the materials used in these devices rarely cause challenges, some problems may result from poor biocompatibility. Thus, an incomplete understanding of the materials may prevent the emergence of certain domains in gastroenterology biomaterials. Despite these obstacles, continuous study and clinical trials are improving the safety and efficacy of devices. With the potential to greatly enhance treatment outcomes and quality of life for millions of patients worldwide, this accomplishment points to a bright future for the profession.
